← Back to search
DYNPORT VACCINE COMPANY LLC
FREDERICK, MD, 21701
Unclaimed
Source Records
No company-reported description yet. Owners can add one after claiming the profile.
Capabilities
Derived from government recordsGov-sourced
- Research and Development in Biotechnology (except Nanobiotechnology)
- Biological Product (except Diagnostic) Manufacturing
- Engineering Services
- Custom Computer Programming Services
- Computer Systems Design Services
- Other Computer Related Services
- Administrative Management and General Management Consulting Services
- Marketing Consulting Services
- Process, Physical Distribution, and Logistics Consulting Services
- Other Management Consulting Services
- Other Scientific and Technical Consulting Services
- Research and Development in the Physical, Engineering, and Life Sciences
Prime contracting experience
13 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF 1500005I DYNPORT VACCINE COMPANY, LLC; TO 15-0109.B1.0052--05 BASE; BIOD CAN 8470038; $59,564 | HHSN272201500005IUSAspending | $1,757,168 | Sep 3, 2026 | Aug 19, 2016 – Aug 30, 2023 |
| Prime | Department of Defense Department of the Army | STABILITY TESTING | — | $17,415,643 | Jun 30, 2026 | Aug 6, 2021 – Aug 15, 2026 |
| Prime | Department of Defense Department of the Army | PROGRAM REPORTING - TECHNICAL | — | $117,632,941 | May 12, 2026 | May 9, 2013 – Mar 11, 2027 |
| Prime | Department of Defense Defense Health Agency | IGF::OT::IGF - RESEARCH&DEVELOPMENT IN SUPPORT OF THE US ARMY MEDICAL MATERIEL DEVELOPMENT ACTIVITY (USAMMDA) FOR THE PERFORMANCE OF A PHASE I, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE LONG-TERM OPHTHALMIC SAFETY OF TAFENOQUINE VERSUS PLACEBO. | W81XWH15D0037USAspending | $24,245,008 | Jan 23, 2026 | Mar 22, 2017 – Jul 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | TASK ORDER 75N93022F00001 BASE AWARD | 75N93022D00016USAspending | $1,028,570 | Jan 14, 2026 | Jan 21, 2022 – Jan 13, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | EPCTU | 75N93022D00016USAspending | $2,265,501 | Apr 17, 2025 | May 15, 2023 – Jul 15, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | PHASE 1 | HHSN272201500005IUSAspending | $4,120,677 | Apr 11, 2025 | May 13, 2021 – Jan 31, 2025 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | IGF::OT::IGF | — | $235,119,971 | Dec 31, 2024 | May 1, 2006 – Jan 30, 2012 |
| Prime | Department of Health and Human Services National Institutes of Health | PHASE I TASK AREA B -21-0013 - BASE | HHSN272201500005IUSAspending | $5,167,891 | Dec 4, 2024 | Dec 14, 2021 – Dec 15, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF 1500005I DYNPORT VACCINE COMPANY, LLC; PHASE 1 CLINICAL TRIALS UNITS FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES; TO 16-0110.B1.0066--05 BASE TASK ORDER FUNDING; CARB CAN 8023349; | HHSN272201500005IUSAspending | $3,860,187 | Aug 8, 2024 | Jun 13, 2017 – Nov 7, 2020 |
| Prime | Department of Defense Defense Contract Management Agency | 199802!2100!1273!MD17 !US ARMY MEDICAL RESEARCH ACQ ACT!DAMD1798C8024 !A!*!* !19971106!19971130!958462681!927921627!003242013!N!03543!DYNTEL CORP !2000 EDMUND HALLEY DR !RESTON !VA!20191!66672!059!51!RESTON !FAIRFAX !VIRGINIA !0001!+000019021453!N!N!000000000000!AN13!RDTE/BIOMEDICAL - ADV TECH DEV !C9B!MEDICAL & DENTAL SUPPLIES & EQ!1000!NOT DISCERNABLE OR CLASSIFIED !2836!3!*!*!*!B!B!*!A !U!R!2!004!C!* !C!N!Z!* !* !N!C!*!A!Z!A!A!A!*!* !*!N!A!C!N!*!*!*!*!*! | — | $803,304,538 | Feb 5, 2024 | Nov 6, 1997 – Jul 23, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | EVALUATION OF CELL LINES PRODUCING A MONOCLONAL ANTIBODY, AND PRODUCTION AND CHARACTERIZATION OF A CGMP MASTER CELL BANK | HHSN272201600005IUSAspending | $1,213,178 | Jul 12, 2023 | Jul 20, 2022 – Aug 18, 2023 |
| Prime | Department of Defense Department of the Army | IGF::OT::IGF CPP PHASE 2 CLINICAL TRIAL | W81XWH15D0037USAspending | $1,685,156 | Aug 10, 2022 | Nov 1, 2016 – Aug 17, 2018 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
No subaward records on record in current sources. Subcontract relationships are never inferred from award keywords.
Agencies supported
- Department of DefenseGov-sourced
- Department of Health and Human ServicesGov-sourced